August 2026

Delegat Group (NZX:DGL) reported a 20% jump in operating NPAT to NZD 61.5 million for FY26, driven by record EBITDA and a 4% rise in global case sales. The Board declared a 22-cent dividend, up 10%, while net debt fell by NZD 51.8 million.

Synlait Milk anticipates a modest improvement in underlying EBITDA for FY26 but expects a substantial net loss after tax, reflecting ongoing operational challenges and a tough first half.

Air New Zealand reported a $242 million net loss after tax for FY2026, hit by soaring fuel costs linked to the Middle East conflict and persistent engine issues. The airline unveiled a new strategy aiming for operational resilience and targeted growth amid ongoing cost pressures.

Comvita Limited has swung back to profitability in FY26, reporting $7.7 million net profit after a $40.5 million capital raise that brought Southeast Asian consumer giant F&N Ventures on board with a near 20% stake.

Channel Infrastructure NZ Limited reported a 47% rise in net profit for H1 2026, driven by expanded fuel storage capacity and upgraded EBITDA guidance, while declaring a 16% higher interim dividend.

Bentley Capital Limited swung back to profitability in FY2026, posting a $255,000 net profit driven mainly by legal settlements and modest investment gains, reversing a prior loss of $878,000.

PRL Global Ltd (ASX: PRG) reported a 52.5% jump in revenue to $2.26 billion for FY2026, alongside a 26.1% rise in net profit after tax. The company declared a higher final dividend of 3 cents per share, reflecting improved earnings despite a dip in total comprehensive income.

Wiseway Group delivered 10.1% revenue growth to $205.6 million in FY26, led by a 22.2% surge in its eCommerce Solutions division, while maintaining EBITDA margins amid cost discipline. The Group declared a fully franked final dividend of 0.6 cents per share.

Green & Gold Minerals posted a $886,828 loss for FY2026 amid a transformative year marked by its ASX listing and expansion into base metals exploration with the Herberton acquisition.

Revolution Private Credit Income Trust (ASX: REV) posted a 6.25% net return for its inaugural period, outperforming its benchmark, and executed an on-market buy-back worth $23 million.

Vault Minerals has secured a key regulatory waiver from the ACCC for its merger with Genesis Minerals, removing a major obstacle and keeping the deal on track for shareholder approval later this year.

Austco Healthcare has delivered record FY26 financial results, driven by strong organic growth, acquisitions, and a growing software maintenance base, positioning the company for sustained earnings momentum.

NEXTDC has swung to a statutory profit of $82.1 million in FY26, driven by a record 202% jump in contracted utilisation and a strategic shift in lease accounting that added a $128.8 million fair value gain. The company’s $3.4 billion capital expenditure underscores its aggressive expansion, including the opening of its first international data centre in Kuala Lumpur.

Kapstream Investment Trust (ASX:KIT) reported a $3.031 million profit and a 1.48% net return for its inaugural period ending June 2026, underperforming its benchmark but completing a 5% unit buy-back post-period.

Dubber Corporation Limited (ASX:DUB) posted a 17% revenue drop in FY26 to $35.1 million, mainly due to a major contract loss in Europe, but narrowed its net loss by 78% excluding impairments and achieved cash flow breakeven in H2.

Almasar Minerals Limited (ASX:AMK) is launching an IPO to fund early-stage exploration across five licences in Saudi Arabia’s Arabian Shield, targeting gold and copper mineralisation.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Nuchev Limited grew revenue by 12% in FY26, driven by domestic expansion, yet saw margins contract and adjusted EBITDA losses deepen to A$4.6 million. The company’s FY27 focus shifts to margin improvement, operating leverage, and cash conversion.

Alfabs Australia delivered an 11% revenue increase and improved free cash flow in FY26, progressing its debt restructuring and setting the stage for dividend reinstatement.

Beonic Limited grew revenue by 5.2% to $23.3 million in FY26, halving its loss and achieving positive operating cash flow, underpinned by a landmark Moroccan airport contract and product innovation.

Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.

Clime Capital has reported an unaudited $13.4 million pre-tax profit for FY26, declared a September quarter dividend, and is considering a special dividend pending audit completion.

Australian Dairy Nutritionals reported a 47% reduction in net loss for FY26, driven by a 66% revenue jump in its nutritional powders segment, which now makes up 70% of total revenue.

Transmetro Corporation lifted its net profit after tax by nearly 50% to $4.489 million for FY26, driven by a 10.4% revenue increase and a 23.4% jump in EBITDA. The hospitality operator also raised its fully franked final dividend to 6 cents per share.